← Evidence library

BIB_326

Hassel JC et al. (NCT Heidelberg + multicentre). Tebentafusp T-cell engager in uveal melanoma — Phase III long-term update. NEJM 2024-2025. The single most important new molecule in uveal melanoma in the past 5 years. (Not directly relevant for cutaneous melanoma patient but establishes uveal as treatable; uveal melanoma is excluded from the patient's IB cutaneous diagnosis.) [Tasks: 18, 19b] Tier: 1 (NEJM phase III) Grade: A Retrieved: 2026-05-15

Evidence grade

A

Tier

1 (NEJM phase III)

Cited by tasks

18, 19b

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_326/findings.md (research corpus). This page is a short context summary — not individualised medical advice.